Upgrade to SI Premium - Free Trial

Form 3 SOPHiA GENETICS SA For: Mar 18 Filed by: Muken Ross

March 18, 2026 9:46 AM
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Muken Ross
(Last) (First) (Middle)
C/O SOPHIA GENETICS INC.
401 PARK DRIVE, FLOOR 5
(Street)
BOSTON MA 02215
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026 		3. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares 200,000
I
By Family Trust (1)
Ordinary Shares 273,093 (2)
D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Share Option (Right to Buy) (3) 02/05/2031 Ordinary Shares 640,000 6.23 D
Share Option (Right to Buy) (3) 07/22/2031 Ordinary Shares 141,509 18 D
Share Option (Right to Buy) (4) 04/03/2033 Ordinary Shares 334,572 4.72 D
Share Option (Right to Buy) (5) 04/02/2034 Ordinary Shares 503,049 4.96 D
Share Option (Right to Buy) (6) 12/18/2034 Ordinary Shares 100,000 3.4 D
Share Option (Right to Buy) (7) 04/02/2035 Ordinary Shares 426,136 3.29 D
Explanation of Responses:
1. Shares are held by the Ross Muken 2026 Irrevocable Trust. The Reporting Person's spouse is the beneficiary. The trust is irrevocable and the Reporting Person does not have the power to direct the trustees with respect to the voting or disposition of the securities held by the trust. A friend of the Reporting Person and an independent attorney serve as co-trustees. The Reporting Person retains the power to remove and replace the trustees. The Reporting Person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
2. Includes 249,158 ordinary shares issuable upon settlement of five restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 6,196 ordinary shares from a May 18, 2022 grant vesting in equal monthly installments through May 18, 2026; (ii) 68,100 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iii) 64,053 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; (iv) 14,358 ordinary shares from a December 18, 2024 grant vesting in equal quarterly installments through December 18, 2028; and (v) 96,451 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.
3. The share options are fully vested and exercisable.
4. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.
5. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.
6. The share option vests and becomes exercisable as to 25% of the ordinary shares on December 18, 2025, and then in equal monthly installments through December 18, 2028.
7. The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.
Remarks:
Exhibit list - Exhibit 24 - Power of Attorney
/s/ Elimara Brunetto as Attorney-in-fact for Ross Muken 03/18/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

ATTACHMENTS / EXHIBITS

EX-24

Categories

SEC Filings